Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD26.RSV.preF + influenza vaccine
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**AD26.RSV.preF + influenza vaccine** is a combination of two vaccines: AD26.RSV.preF (an adenovirus serotype 26 vector–based vaccine encoding a prefusion-stabilized RSV fusion protein) and a high-dose seasonal influenza vaccine (commonly Fluzone-HD)[1][5]. AD26.RSV.preF stimulates humoral and cellular immunity against respiratory syncytial virus (RSV), while the influenza vaccine elicits an antibody response to the influenza virus. This combination is primarily developed for coadministration in older adults, aiming to protect against both RSV and seasonal influenza. Mechanistically, AD26.RSV.preF delivers genetic material encoding the stabilized RSV fusion protein, inducing virus-neutralizing antibodies and Th1-skewed T-cell immunity[3]. The influenza vaccine provides immunity against circulating influenza strains by introducing antigens from these viruses.
- Brand names
- Fluzone-HD
- Other names
- Ad26.RSV.preF/RSV preF protein + high-dose influenza vaccineRSV vaccine + high-dose influenza vaccine
02
Targets
HA (Hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on AD26.RSV.preF + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD26.RSV.preF + influenza vaccine.